Gillette and EA SPORTS FC Partner to Elevate the Gaming Experience for Fans On and Off the Pitch
BOSTON--(BUSINESS WIRE)--For over a century, Gillette, the world's leading expert in men's grooming, and EA SPORTS FC, a leader in sports entertainment with 30+ years history, have built reputations synonymous with precision, performance, and innovation. Today, these two global brands partner with the goal to transform how fans and gamers around the world experience football both on and off the pitch.
This collaboration shows how the value of Gillette's superior performance and precision extends beyond grooming for its consumers...
Share
The partnership kicked off in January with EA SPORTS FC™ 25 featuring Gillette as part of in-game LED ad banner signage and is now moving to the next level offering Football Ultimate Team™ packs, available to redeem* for a limited time. To elevate this experience, Gillette is partnering with global content creators to showcase their 'razor-sharp' skills on and off the pitch. Together, Gillette and EA SPORTS FC aspire to inspire athletes, fans, and gamers everywhere to feel sharp and play sharp.
Building on Gillette's storied legacy in sports, recently strengthened by their three-year licensing partnership with the UEFA Champions League and New England Revolution jersey sponsorship, this collaboration further elevates Gillette's global presence across gaming and football. Gillette has consistently grown its presence in football and is dedicated to fostering the growth of the sport at all levels.
'This partnership with EA SPORTS FC represents a defining moment for Gillette as we celebrate the momentum and continued growth of the brand's presence in football on and off the pitch globally,' shared Daniel Ordoñez, Vice President Gillette Global Brand Franchise. 'As we build upon our commitment to the sport, we're excited to deepen our roots while connecting with the next generation of men and engaging the larger global football community in authentic ways.'
Gillette's dedication shines through the precision-engineering of its products, crafted to deliver an unparalleled grooming experience. This collaboration shows how the value of Gillette's superior performance and precision extends beyond grooming for its consumers, but also to its partnership like EA SPORTS FC 25. When fans feel their best, they play their best.
'We're thrilled to partner with Gillette in EA SPORTS FC 25, as their commitment and impact continues to grow in football,' said Charlie Villiers, Sr. Director, Franchise Marketing EA SPORTS FC. 'Through this collaboration, we're able to celebrate our shared passion for the world's game and create innovative and authentic ways to engage with both the Gillette and EA SPORTS FC communities.'
Connecting hundreds of millions of football fans through console, mobile, online, and esports products, EA SPORTS FC boasts an unparalleled global audience. This partnership represents a strategic step for Gillette, leveraging EA SPORTS FC's dedicated player community to further connect with gamers. By aligning with EA SPORTS FC, Gillette is deepening its integration in both sports and gaming, amplifying its brand presence, and reinforcing its commitment to engaging consumers in innovative and meaningful ways.
For more information about the Gillette x EA SPORTS FC partnership and activation on EA SPORTS FC 25, visit https://www.ea.com/redeem/gillette/
*This activation is live in:
US (May 1 st, 2025 - August 31 st, 2025)
Germany (May 7 th, 2025 – June 30 th, 2025)
UK (June 15 th, 2025 - June 30 th, 2025)
Before redeeming a code, log into your EA Account and make sure that's the EA Account that you use in EA SPORTS FC 25. Pay attention to the redemption conditions and validity period. A code cannot be redeemed after it expires.
For FAQs and Terms and Conditions, go to FAQ (English / German).
About Gillette
For more than 115 years, Gillette has delivered precision technology and unrivaled product performance – improving the lives of over 800 million consumers around the world. From shaving and body grooming, to skin care and sweat protection, Gillette offers a wide variety of products including razors, shave gel (gels, foams and creams), skin care, after shaves, antiperspirants, deodorants and body wash. For more information and the latest news on Gillette, visit www.gillette.com. To see our full selection of products, visit www.gillette.com. Follow Gillette on X, Facebook and Instagram.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always ®, Ambi Pur ®, Ariel ®, Bounty ®, Charmin ®, Crest ®, Dawn ®, Downy ®, Fairy ®, Febreze ®, Gain ®, Gillette ®, Head & Shoulders ®, Lenor ®, Olay ®, Oral-B ®, Pampers ®, Pantene ®, SK-II ®, Tide ®, Vicks ®, and Whisper ®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at https://www.pg.com/news.
About EA
Electronic Arts (NASDAQ: EA) is a global leader in digital interactive entertainment. The Company develops and delivers games, content and online services for Internet-connected consoles, mobile devices and personal computers.
In fiscal year 2024, EA posted GAAP net revenue of approximately $7.6 billion. Headquartered in Redwood City, California, EA is recognized for a portfolio of critically acclaimed, high-quality brands such as EA SPORTS FC™, Battlefield™, Apex Legends™, The Sims™, EA SPORTS™ Madden NFL, EA SPORTS™ College Football, Need for Speed™, Dragon Age™, Titanfall™, Plants vs. Zombies™ and EA SPORTS F1 ®. More information about EA is available at www.ea.com/news.
EA, EA SPORTS, EA SPORTS FC, Battlefield, Need for Speed, Apex Legends, The Sims, Dragon Age, Titanfall, and Plants vs. Zombies are trademarks of Electronic Arts Inc. John Madden, NFL, and F1 are the property of their respective owners and used with permission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Gonçalo Ramos and Kang-in Lee allowed to leave PSG
Gonçalo Ramos (23) and Lee Kang-in (24) will be allowed to leave Paris Saint-Germain this summer, according to a report from L'Équipe. The pair have featured sparingly throughout the campaign. Ramos suffered an ankle injury in the first game of the season, which sidelined him for several months. He has nonetheless gone on to make 41 appearances in all competitions, scoring 18 goals in that time, however, starts have been hard to come by. Luis Enrique has preferred Ousmane Dembélé in the No.9 position this season. Advertisement Lee also has 45 appearances in all competitions, but like Ramos, he has started rarely. He has just four starts in the UEFA Champions League and he hasn't been included in the starting XI during the knockout phases of the competition. Both have contracts that run until 2028 but will be allowed to leave, for the right price, this summer. Following their triumph in the Champions League, they are under no obligation to sell. GFFN | Luke Entwistle
Business Wire
24 minutes ago
- Business Wire
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, 'Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,' the study authors presented their findings that demonstrated KROS 101's capability to act as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mechanisms of action. The study authors also indicated their study showed KROS 101 enhanced T cell function by promoting proliferation and increasing cytotoxicity, enhancing the immune response by boosting cytokine production and tumor cancer cell killing. In addition, the study found that KROS101 reduced T reg-mediated suppression by reducing T reg populations, which reverses immune system suppression and enhances effector T cell activity. Further, the study showed KROS to be superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg decrease, enhancing tumor cell cytotoxicity and preventing T cell exhaustion. TRX518 was previously in clinical trials. The presentation can be accessed here. John Yu, M.D., Kairos CEO commented, 'These results strongly support continued study of KROS101 as a cancer immunotherapy, as they show strong activity in boosting the immune system while targeting and killing tumor cells. Its dual mechanism of action provides significant opportunity to a market that remains in desperate need of new solutions. We continue to believe that KROS 101 has the potential to help optimize cancer treatment and we look forward to discussing these findings with the medical and scientific communities while providing additional progress updates as appropriate.' About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, with the trials aimed at addressing significant unmet medical needs. For more information, visit CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential' or 'hopes' or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma's Annual Report on Form 10-K and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.
Business Wire
25 minutes ago
- Business Wire
o9 is Raising the Bar for Enterprise Planning and Execution
DALLAS--(BUSINESS WIRE)-- o9, a leading AI-powered software platform for enterprise planning and execution, today announced new capabilities centered on specialized AI agents and self-learning models within its Digital Brain™ Platform. These advancements take intelligence, automation, and value-creation speed to the next level. The platform enables the digitization of processes from execution to long-range planning, across the supply chain, commercial, and P&L domains. It helps create a boundaryless operating model for optimized, synchronized decision-making in response to rapidly emerging and evolving market risks and opportunities. Leading manufacturers, retailers, distributors and service providers across 30-plus industry verticals use the o9 Digital Brain™ to connect the islands of data and tribal knowledge into its patented Enterprise Knowledge Graph (EKG), enabling integrated planning and execution across the enterprise. o9 clients have reported value generation in the hundreds of millions per year, driven by inventory savings, cost of goods reduction, and improvements in customer service and productivity. The value proof points o9's clients are experiencing strongly validate o9's founding premise: enhancing enterprise planning and execution capabilities is the top value creation driver for any business navigating an increasingly volatile and complex world. o9 invested in deep R&D and pilot programs with strategic clients to develop the following capabilities, which are now generally available. Specialized o9 AI Agents for Planning and Execution The Digital Brain now features specialized AI agents that enhance the productivity and expertise of management, planners, and individuals in front-line operations roles. o9 built these AI Agents by combining generative and agentic AI with its patented Enterprise Knowledge Graph (EKG), which connects data and tribal knowledge into a system of record of digital knowledge. These new AI Agents can analyze large volumes of data to identify risks and opportunities while answering key management questions that o9 refers to as the 3Ws: What happened and why? What is likely to happen? What cross-functional actions should be taken to improve the plan? Performance Post-Game-Analysis (PGA) Solutions with Inbuilt Learning Models for Continuous Improvement o9's PGA solutions powered by inbuilt learning models, provide insights into why the execution deviated from the plan and where the value leakage is happening. These capabilities are the ultimate catalyst for driving continuous improvement. The o9 PGA solutions include automated identification of value leakage and performance gaps, root-cause analysis algorithms, and AI-powered storytelling. Self-Service Fast Innovation Platform: Enabling Enterprises to Own the Improvement and Drive Change Faster This new offering will allow o9 clients to improve and extend capabilities within their existing o9 Digital Brain™ Platform through a self-service model. Users can continuously improve, innovate, and be in control of their own use of the platform to fine-tune capabilities and drive adoption of business processes. No-code and low-code AI agents will make it easier for innovation to leverage the platform's flexibility. Features include the ability to continuously extend and improve deployed solutions, build unique differentiated capabilities into standard processes, and modernize legacy applications. Powered by these innovations, o9 is helping enterprises to build highly effective boundless operating models to drive performance excellence in highly volatile and fast-changing environments. To learn more, visit About o9 o9 is a leading AI-powered platform for integrated business planning and decision-making for the enterprise. Whether it is driving demand, aligning demand and supply, or optimizing commercial initiatives, any planning process can be made faster and smarter with o9's AI-powered digital solutions. o9 brings together technology innovations—such as graph-based enterprise modeling, big data analytics, advanced algorithms for scenario planning, collaborative portals, easy-to-use interfaces and cloud-based delivery—into one platform. For more information, please visit
